Page 3 - Adjuvant News Today

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

Immunotherapy given before and after surgery significantly improved outcomes in patients with operable non-small cell lung cancer.

– In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28% – – Up to 80%... | April 16, 2023

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1Up to 80% of people with this type

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanomaCAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE

MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of... | April 6, 2023

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trialCAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering

The German Working Group for Covid Vaccine Analysis – which includes over 60 scientists, doctors, lawyers, and journalists – published their “Summary of Preliminary Findings” on the toxic [...]

Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy

First-in-human study investigating the safety and immunogenicity of ISA's proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs